- Report
- October 2025
- 195 Pages
Global
From €3145EUR$3,545USD£2,730GBP
€3494EUR$3,939USD£3,034GBP
- Report
- September 2025
- 150 Pages
Global
From €5278EUR$5,950USD£4,582GBP
- Report
- September 2025
- 150 Pages
United States
From €5278EUR$5,950USD£4,582GBP
- Report
- September 2025
- 150 Pages
Middle East
From €5278EUR$5,950USD£4,582GBP
- Report
- August 2025
- 184 Pages
Global
From €3145EUR$3,545USD£2,730GBP
€3494EUR$3,939USD£3,034GBP
- Report
- February 2024
- 115 Pages
Global
From €4213EUR$4,750USD£3,658GBP
- Report
- May 2024
- 182 Pages
Global
From €3992EUR$4,500USD£3,466GBP
The Active Pharmaceutical Ingredients (API) CDMO market is a subset of the pharmaceutical manufacturing industry. It involves the production of APIs, which are the active ingredients in drugs that are responsible for their therapeutic effects. CDMOs provide a range of services, from drug development and manufacturing to packaging and distribution. They are often used by pharmaceutical companies to outsource the production of APIs, allowing them to focus on other aspects of drug development.
CDMOs are typically specialized in specific areas of drug production, such as synthesis, formulation, and analytical testing. They are also responsible for ensuring that the APIs they produce meet the necessary regulatory standards.
Some of the major players in the API CDMO market include Lonza, Patheon, Boehringer Ingelheim, Cambrex, and Evonik. Show Less Read more